Fragment-based drug discovery (FBDD) has grown and matured to a point where it is valuable to keep track of its extent and details of application. This Perspective summarizes successful fragment-to-lead stories published in 2019. It is the fifth in a series that started with literature published in 2015. The analysis of screening methods, optimization strategies, and molecular properties of hits and leads are presented in the hope of informing best practices for FBDD. Moreover, FBDD is constantly evolving, and the latest technologies and emerging trends are summarized. These include covalent FBDD, FBDD for the stabilization of proteins or protein-protein interactions, FBDD for enzyme activators, new screening technologies, and advances in l...
Fragment-based drug discovery (FBDD) is well suited for discovering both drug leads and chemical pro...
Fragment-based drug discovery (FBDD) is an important technology in drug discovery that seeks to iden...
This Perspective is the eighth in an annual series that summarizes successful fragment-to-lead (F2L)...
Fragment-based drug discovery (FBDD) has grown and matured to a point where it is valuable to keep t...
This Perspective, the fourth in an annual series, summarizes fragment-to-lead (F2L) success stories ...
Fragment-based drug discovery (FBDD) is now well-established as a technology for generating new chem...
The popularity of fragment-based drug discovery (FBDD) is demonstrated by the number of recent succe...
Fragment-based lead discovery (FBLD), often also called fragment-based drug discovery (FBDD), is evo...
This Perspective is the seventh in an annual series that summarizes successful Fragment-to-Lead (F2L...
This book presents a company-based view of the recent progresses in fragment-based drug discovery (F...
Fragment-based lead discovery (FBLD), often also called fragment-based drug discovery (FBDD), is evo...
Fragment-based lead discovery (FBLD) is a powerful application for developing ligands as modulators ...
Fragment-Based Drug Discovery (FBDD) is here to stay. Validated as a technology with the delivery of...
Fragment-based drug discovery (FBDD) is a highly interdisciplinary field, rich in ideas integrated f...
Fragment-based drug discovery (FBDD) is a highly interdisciplinary field, rich in ideas integrated f...
Fragment-based drug discovery (FBDD) is well suited for discovering both drug leads and chemical pro...
Fragment-based drug discovery (FBDD) is an important technology in drug discovery that seeks to iden...
This Perspective is the eighth in an annual series that summarizes successful fragment-to-lead (F2L)...
Fragment-based drug discovery (FBDD) has grown and matured to a point where it is valuable to keep t...
This Perspective, the fourth in an annual series, summarizes fragment-to-lead (F2L) success stories ...
Fragment-based drug discovery (FBDD) is now well-established as a technology for generating new chem...
The popularity of fragment-based drug discovery (FBDD) is demonstrated by the number of recent succe...
Fragment-based lead discovery (FBLD), often also called fragment-based drug discovery (FBDD), is evo...
This Perspective is the seventh in an annual series that summarizes successful Fragment-to-Lead (F2L...
This book presents a company-based view of the recent progresses in fragment-based drug discovery (F...
Fragment-based lead discovery (FBLD), often also called fragment-based drug discovery (FBDD), is evo...
Fragment-based lead discovery (FBLD) is a powerful application for developing ligands as modulators ...
Fragment-Based Drug Discovery (FBDD) is here to stay. Validated as a technology with the delivery of...
Fragment-based drug discovery (FBDD) is a highly interdisciplinary field, rich in ideas integrated f...
Fragment-based drug discovery (FBDD) is a highly interdisciplinary field, rich in ideas integrated f...
Fragment-based drug discovery (FBDD) is well suited for discovering both drug leads and chemical pro...
Fragment-based drug discovery (FBDD) is an important technology in drug discovery that seeks to iden...
This Perspective is the eighth in an annual series that summarizes successful fragment-to-lead (F2L)...